Skip to main content
. 2013 Sep 3;73(12):2152–2159. doi: 10.1136/annrheumdis-2013-203742

Figure 2.

Figure 2

Changes in total van der Heijde-Sharp (vdH-S) scores from baseline to week 52 (A) and from week 24 to week 52 (B). GLM, golimumab; MTX, methotrexate; PBO, placebo.